Editorial. Weighty matter

Semaglutide: Need for caution | Photo Credit: th-online Administrator After the semaglutide molecule, used to treat type 2 diabetes and/or weight loss, went off patent last Friday, a flood of branded generics entered the market. The reaction has ranged from euphoria to alarm, as these generic versions are selling at 50-80 per cent lower than the price for the hitherto patented brands, Ozempic and Wegovy. In other words, the monthly cost of these generics is set to drop from ₹12,000 to ₹3,000 or...